CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2013-09-03): Safety committee raises concern over tivantinib for liver cancer


Safety committee raises concern over tivantinib for liver cancer

Last Updated: 2013-09-03 13:40:23 -0400 (Reuters Health)

(Reuters) - Drugmaker ArQule Inc said a late-stage trial of its liver cancer drug tivantinib showed high incidence of leukopenia in patients, leading to an independent safety committee recommending the company lower the drug dose.

The Data Monitoring Committee recommended that the study dose be reduced from 240 mg twice daily to 120 mg, and the patients be monitored to confirm the safety profile of the lower dose.

ArQule and its partner Daiichi Sankyo Inc accepted the recommendation of the committee and will file a protocol amendment with regulatory authorities, ArQule said in a regulatory filing.

Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. The companies were testing tivantinib as a treatment for hepatocellular cancer, the most common type of liver cancer.

The companies said they were unable to comment on whether the timeline for recruitment of the trial might be delayed from original estimates as a result of the proposed change and the subsequent data review, as the study was in the early stages of recruitment.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.